Study for AZD4360 in Participants With Advanced Solid Tumours

This study is testing a new drug called AZD4360 for people with advanced pancreatic cancer, stomach cancer, or bile duct cancer whose tumors have a protein called Claudin 18.2 on their surface. This is an early-phase dose-finding study to evaluate safety and early effectiveness. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction cancer, or biliary tract cancer - Your tumor tests positive for Claudin 18.2 expression - You have received at least one prior round of chemotherapy - Your overall health and organ function are adequate **You may NOT be eligible if...** - You have not received any prior treatment - Your tumor does not express Claudin 18.2 - You have received prior RAS-targeted therapy (for some study arms) - You are pregnant or breastfeeding - You cannot swallow tablets Talk to your doctor to see if this trial is right for you.